Opus Genetics (NASDAQ:IRD) Sees Large Volume Increase After Analyst Upgrade

Key Points

• Opus Genetics shares surged on heavy trading volume after Wedbush raised its price target to $13 from $10 while maintaining an outperform rating. More than 4.7 million shares traded, up 262% from the prior session.
• The company reported positive early results from the Phase 1/2 BIRD-1 trial, with all five low-dose participants showing meaningful visual improvement and no serious adverse events. Opus said FDA discussions support a potential Phase 3 trial beginning in 2027 and expects cash runway into 2029.
• Analyst sentiment is broadly bullish, with a “Moderate Buy” consensus and average price target of $11.92, though the clinical results remain preliminary and require validation from additional cohorts and Phase 3 execution.

Shares of Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) saw strong trading volume on Thursday after Wedbush raised their price target on the stock from $10.00 to $13.00. Wedbush currently has an outperform rating on the stock. 4,770,454 shares were traded during trading, an increase of 262% from the previous session's volume of 1,316,189 shares.The stock last traded at $6.2060 and had previously closed at $5.73.

A number of other analysts have also recently weighed in on the stock. Zacks Research raised shares of Opus Genetics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Leerink Partners assumed coverage on Opus Genetics in a report on Thursday, May 21st. They set an "outperform" rating and a $10.00 price objective on the stock. Wall Street Zen raised Opus Genetics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Guggenheim initiated coverage on Opus Genetics in a research report on Thursday, June 4th. They issued a "buy" rating and a $16.00 target price for the company. Finally, Royal Bank Of Canada cut their price target on Opus Genetics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $11.92.

Insiders Place Their Bets

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of the company's stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the sale, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 28,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total value of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company's stock, valued at approximately $2,525,942.50. The trade was a 4.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 57,331 shares of company stock valued at $213,749 over the last 90 days. 11.70% of the stock is currently owned by company insiders.

Opus Genetics News Summary

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics reported positive low-dose Cohort 1 results from the Phase 1/2 BIRD-1 trial of OPGx-BEST1. All five participants showed clinically meaningful visual-function improvement, while no serious adverse events or dose-limiting toxicities were observed. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: The company said the FDA aligned with a potential pivotal endpoint and that a Phase 3 trial could begin dosing in 2027. Cohort 2 was over-enrolled, with three-month data expected in the second quarter of 2027.
• Positive Sentiment: Opus Genetics expects to have cash runway into 2029, potentially supporting multiple clinical milestones and reducing near-term financing pressure.
• Positive Sentiment: Analysts raised or reaffirmed bullish views following the data. Oppenheimer increased its price target to $20 from $10, while Wedbush raised its target to $13 from $10. BTIG and Chardan maintained Buy ratings with $12 and $13 targets, respectively; HC Wainwright reaffirmed Buy with an $8 target. Wedbush Raises Price Target
• Positive Sentiment: Unusually heavy call-option activity, roughly 681% above typical volume, suggests speculative traders were positioning for further gains.
• Neutral Sentiment: The results remain early-stage and involve only five participants in the initial low-dose cohort. Additional follow-up, Cohort 2 results and successful Phase 3 execution will be needed to validate the therapy.
• Negative Sentiment: CFO Robert Gagnon sold 28,000 shares for $127,120 to cover tax withholding from vested equity awards. The sale was a relatively small reduction in his holdings and appears administrative, but insider selling can still weigh modestly on sentiment.

Hedge Funds Weigh In On Opus Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Opaleye Management Inc. lifted its stake in shares of Opus Genetics by 0.4% in the 2nd quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company's stock valued at $4,624,000 after purchasing an additional 5,000 shares during the period. Engineers Gate Manager LP acquired a new stake in shares of Opus Genetics during the 2nd quarter worth approximately $50,000. Squarepoint Ops LLC acquired a new stake in shares of Opus Genetics during the 2nd quarter worth approximately $1,360,000. Nantahala Capital Management LLC bought a new stake in shares of Opus Genetics in the 2nd quarter valued at $12,582,185. Finally, Empowered Funds LLC bought a new stake in shares of Opus Genetics in the 2nd quarter valued at $173,000. Institutional investors and hedge funds own 14.97% of the company's stock.

Opus Genetics Trading Up 7.8%

The stock's 50-day moving average is $3.82 and its 200-day moving average is $4.30. The company has a market cap of $510.69 million, a price-to-earnings ratio of -4.54 and a beta of 0.58.

Opus Genetics (NASDAQ:IRD - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. The business had revenue of $0.76 million during the quarter, compared to analysts' expectations of $2.63 million. As a group, analysts predict that Opus Genetics, Inc. will post -0.99 EPS for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.